Health Canada has issued a strong warning against the purchase and use of unauthorized or counterfeit GLP-1 drugs, including the widely recognized semaglutide, an active ingredient...
Novo Nordisk Canada is set to introduce lower-priced versions of its widely used medications, Ozempic and Wegovy, in a strategic move to compete with upcoming generics....
URGENT UPDATE: Novo Nordisk Canada has just announced plans to introduce lower-priced versions of its popular diabetes and weight-loss drugs, Ozempic and Wegovy, as competition from...
Health Canada is currently reviewing nine submissions for generic versions of widely used weight loss medications, a move that could significantly reduce prices for Canadians this...
UPDATE: The U.S. Food and Drug Administration (FDA) has just approved Novo Nordisk’s groundbreaking weight-loss pill, Wegovy, marking a significant milestone in the fight against obesity....
As 2026 approaches, several pivotal health issues are poised to shape Canada’s healthcare landscape. The CBC Health Unit has identified key stories to monitor, including innovations...
The World Health Organization (WHO) has conditionally endorsed the use of GLP-1 medications, such as Ozempic, for the treatment of obesity. This recommendation, issued on December...
The recent turmoil surrounding Novo Nordisk highlights a significant shift in the pharmaceutical landscape, particularly regarding the company’s weight-loss drug, Ozempic. Following a profit warning, Novo...
Africa’s largest pharmaceutical company, Aspen Pharmacare Holdings Ltd., is set to produce affordable generic versions of popular obesity drugs, including Ozempic, Wegovy, and Mounjaro, starting in...
Health Canada has granted approval for Ozempic to reduce the risk of kidney deterioration in adults with Type 2 diabetes. This decision comes after substantial evidence...
